These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Nishijima TF; Shachar SS; Nyrop KA; Muss HB Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115 [TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
5. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment]. Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981 [TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
7. PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study. Ács B; Madaras L; Tőkés AM; Kovács AK; Kovács E; Ozsvári-Vidákovich M; Karászi Á; Birtalan E; Dank M; Szász AM; Kulka J Breast; 2017 Oct; 35():69-77. PubMed ID: 28651116 [TBL] [Abstract][Full Text] [Related]
8. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. Kassardjian A; Shintaku PI; Moatamed NA PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601 [TBL] [Abstract][Full Text] [Related]
9. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979 [TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. Luo W; Wang Z; Tian P; Li W J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers for checkpoint inhibition in hematologic malignancies. Atanackovic D; Luetkens T Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689 [TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse effects of the immune checkpoint inhibitors. Collins LK; Chapman MS; Carter JB; Samie FH Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531 [TBL] [Abstract][Full Text] [Related]
14. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. Soo RA; Kim HR; Asuncion BR; Fazreen Z; Omar MFM; Herrera MC; Yun Lim JS; Sia G; Soong R; Cho BC Lung Cancer; 2017 Mar; 105():17-22. PubMed ID: 28236980 [TBL] [Abstract][Full Text] [Related]
15. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer]. Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibition in ovarian cancer. Hamanishi J; Mandai M; Konishi I Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470 [TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Blockade in Breast Cancer Therapy. Bu X; Yao Y; Li X Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694 [TBL] [Abstract][Full Text] [Related]
18. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Wang X; Bao Z; Zhang X; Li F; Lai T; Cao C; Chen Z; Li W; Shen H; Ying S Oncotarget; 2017 Aug; 8(35):59901-59914. PubMed ID: 28938692 [TBL] [Abstract][Full Text] [Related]
20. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]